Collegium Pharmaceutical (NASDAQ:COLL) Issues Quarterly Earnings Results, Beats Expectations By $0.36 EPS

Collegium Pharmaceutical (NASDAQ:COLL) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $2.25 earnings per share for the quarter, beating the consensus estimate of $1.89 by $0.36, Briefing.com reports. The company had revenue of $209.36 million during the quarter, compared to analysts’ expectations of $191.25 million. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.Collegium Pharmaceutical’s revenue for the quarter was down 18.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.61 earnings per share. Collegium Pharmaceutical updated its FY 2025 guidance to EPS and its FY 2025 guidance to EPS.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded up $1.64 during trading hours on Friday, hitting $42.30. 864,974 shares of the stock were exchanged, compared to its average volume of 414,440. The company’s fifty day simple moving average is $35.70 and its two-hundred day simple moving average is $32.80. The company has a market cap of $1.33 billion, a PE ratio of 26.27 and a beta of 0.61. The company has a debt-to-equity ratio of 2.94, a quick ratio of 1.10 and a current ratio of 1.54. Collegium Pharmaceutical has a 1-year low of $23.23 and a 1-year high of $43.06.

Analyst Ratings Changes

COLL has been the subject of several research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Wednesday, October 8th. HC Wainwright upped their target price on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 23rd. Finally, Needham & Company LLC restated a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.25.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 17,478 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $38.42, for a total value of $671,504.76. Following the transaction, the executive vice president owned 70,264 shares in the company, valued at $2,699,542.88. The trade was a 19.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gino Santini sold 5,405 shares of Collegium Pharmaceutical stock in a transaction on Friday, August 15th. The shares were sold at an average price of $37.19, for a total transaction of $201,011.95. Following the completion of the sale, the director owned 95,042 shares of the company’s stock, valued at $3,534,611.98. This represents a 5.38% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 74,133 shares of company stock valued at $2,899,504. 2.51% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Collegium Pharmaceutical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after buying an additional 825 shares during the last quarter. Millennium Management LLC lifted its stake in Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Collegium Pharmaceutical by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Collegium Pharmaceutical by 218.7% during the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after buying an additional 90,255 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Collegium Pharmaceutical by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after acquiring an additional 2,592 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.